Whole-blood transcriptomics reveal molecular compatibility and complementarity across advanced therapies in ulcerative colitis

Authors: Alsoud, Dahham; Abdurahiman, Saeed; Sabino, Joao; Ferrante, Marc; Vermeire, Severine; Verstockt, Bram

Source journal: Journal of Crohn's & colitis (2026-11-07)

DOI: 10.1093/ecco-jcc/jjag194

Abstract

BACKGROUND AND AIMS: Despite an expanding therapeutic landscape, an efficacy ceiling persists with advanced monotherapies in ulcerative colitis (UC). We used longitudinal whole-blood transcriptomics to characterize molecular compatibility, therapy-specific effects with potential complementarity, and potential cross-therapy resistance correction. METHODS: Adults with endoscopically active UC (Mayo endoscopic sub-score [MES] >/=2) initiating anti-tumor necrosis factor (anti-TNF), vedolizumab (VDZ), tofacitinib (TFC), or ustekinumab (UST) underwent whole-blood RNA sequencing at baseline and/or post-induction endoscopy. Endoscopic improvement was defined as MES /=50% of the corresponding resistance effect. RESULTS: Among 314 treatment cycles from 234 patients (514 RNA samples), 47.6% achieved endoscopic improvement. Anti-TNF, VDZ, and TFC response-associated signatures were broadly concordant across molecular layers while retaining therapy-specific features. UST showed no significant response-associated DEGs but retained distinct pathway- and TF-level signals. In parallel, cross-therapy response-associated effects opposed resistance-associated features, with correlations of -0.89 to -1.00 for genes, -0.64 to -0.84 for biological processes, and -0.52 to -0.76 for TF activities. Against anti-TNF resistance, VDZ met the potential-correction criterion for 70% of DEGs, 79% of biological processes, and 96% of TF activities, including all 20 resistance processes with the largest absolute enrichment scores. CONCLUSIONS: Whole-blood transcriptomics identified compatible shared responses, therapy-specific molecular effects, and potential cross-therapy compensation. These findings generate hypotheses for biologically informed combination strategies requiring prospective validation, rather than evidence of efficacy or synergy.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.